Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Apr 12;9(1):1744898.
doi: 10.1080/2162402X.2020.1744898.

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Fabrice Barlesi  1 , Adrien Dixmier  2 , Didier Debieuvre  3 , Christophe Raspaud  4 , Jean-Bernard Auliac  5 , Nicolas Benoit  6 , Pierre Bombaron  7 , Denis Moro-Sibilot  8 , Clarisse Audigier-Valette  9 , Bernard Asselain  10 , Thomas Egenod  11 , Audrey Rabeau  12 , Jérôme Fayette  13 , Myriam Locatelli Sanchez  14 , Jean-Luc Labourey  15 , Virginie Westeel  16 , Pauline Lamoureux  17 , François-Emery Cotte  17 , Victoria Allan  18 , Melinda Daumont  19 , Juliette Dumanoir  17 , Dorothée Reynaud  17 , Christophe Yannick Calvet  17 , Nicolas Ozan  17 , Maurice Pérol  20
Affiliations
Randomized Controlled Trial

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

Fabrice Barlesi et al. Oncoimmunology. .

Abstract

EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and initiating treatment with nivolumab were recruited from 146 sites in France. This analysis included only patients with non-small cell lung cancer (NSCLC) who received ≥1 nivolumab infusion, and evaluated patient characteristics at the time of nivolumab initiation and its effectiveness and safety after a median follow-up of 18 months. A total of 1,420 patients with NSCLC were included, most of whom had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 (82.9%), non-squamous histology (69.2%) and stage IV disease (91.4%). Brain metastases were present in 19.9% of patients. Nivolumab was a second-line or ≥third-line regimen in 73.6% and 26.1% of patients, respectively. Almost all patients had prior chemotherapy (99.7%). Median overall survival was 11.2 months (95% confidence interval [CI]: 10.0-12.4). ECOG PS, smoking status, corticosteroids at baseline, epidermal growth factor receptor mutation status, presence of symptomatic brain metastases and treatment-related adverse events (TRAEs) were independent predictors of survival. Grade 3 and 4 TRAEs were reported in 105 (7.4%) and 12 (0.8%) patients, respectively; no treatment-related deaths were reported. Preliminary results of the EVIDENS study confirm the effectiveness and safety of nivolumab, mostly in pre-treated advanced NSCLC patients, with similar benefits to those observed in the phase III randomized clinical trials, despite a broader study population.

Keywords: EVIDENS; france; nivolumab; non-small cell lung cancer; observational study.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival. CI, confidence interval; OS, overall survival
Figure 2.
Figure 2.
Progression-free survival. CI, confidence interval; PFS, progression-free survival
See this image and copyright information in PMC

References

    1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F.. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–8. doi:10.1016/j.ejca.2018.07.005. - DOI - PubMed
    1. National Cancer Institute . The essential facts and figures of cancer in France. 2019. [accessed 2019 February26]. http://www.e-cancer.fr/Actualites-et-evenements/Actualites/L-Institut-pu....
    1. Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.21551. - DOI - PubMed
    1. Grapatsas K, Leivaditis V, Tsilogianni Z, Haussmann E, Kaplunov V, Dahm M, Zarogoulidis P, Hohenforst-Schmidt W, Tsakiridis K, Foroulis C, et al. Epidemiology, risk factors, symptomatology, TNM classification of non small cell lung cancer. An overview while waiting the 8th TNM classification. Oncomedicine. 2017;2:14–23. doi:10.7150/oncm.17097. - DOI
    1. Couraud S, Westeel V, Ranchon F, Toffart A-C, Souquet P-J, Editorial board of the 2019 edition. Non-small cell lung cancer. Auvergne Rhône-Alpes guidelines in thoracic oncology. 2019. update 2019 [accessed 2019 May29]. https://ressources-aura.fr/wp-content/uploads/2018/12/CBNPC_2019_VDEF.pdf.

Publication types

Associated data